Timothy Schulz-Utermoehl
Scientist with extensive 20+ years drug discovery & development expertise gained at MSD, AstraZeneca, Shire and Chronos Therapeutics, leading early drug discovery programs. Also was head of DMPK at Sygnature Discovery. Co-founder of multiple UK-based start-ups including Polleo Pharma (Psychiatry, successful exit in 2016), Belfry Therapeutics (Anti-infectives), Pandeia Therapeutics (Neurodegeneration) and Pencil Biosciences (Next generation gene editing). Holds a BSc (Hons) in Pharmacology/Physiology from the University of Leeds, an MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a PhD in Biochemistry from Imperial College plus 2 years of industrial post-doctoral research at Novo Nordisk.
Title of the presentation:
Bacterial Cell Targeted RNA Therapeutics